Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Antineoplastic Agents
/ pharmacology
Antineoplastic Combined Chemotherapy Protocols
Benzamides
Carcinoma, Hepatocellular
/ drug therapy
Humans
Liver Neoplasms
/ drug therapy
Niacinamide
/ pharmacology
Nitriles
Phenylthiohydantoin
Phenylurea Compounds
/ pharmacology
Sorafenib
/ pharmacology
Treatment Outcome
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
26
05
2020
accepted:
31
05
2020
pubmed:
18
6
2020
medline:
22
6
2021
entrez:
18
6
2020
Statut:
ppublish
Résumé
Androgen receptor as assessed by immunohistochemistry is expressed in a high proportion of patients with hepatocellular carcinoma (HCC). Enzalutamide at 160 mg orally daily is safe and tolerable in patients with advanced HCC but has no single-agent antitumor activity. Enzalutamide, a CYP3A4 inducer, at a standard dose of 160 mg reduces the exposure of sorafenib, a CYP3A4 substrate. Enzalutamide and sorafenib is safe and tolerable in patients with advanced HCC, but the addition of enzalutamide to sorafenib did not enhance the antitumor activity of sorafenib. Androgen receptor (AR) interference is deleterious to hepatocellular carcinoma (HCC) in preclinical models. This is a multicenter, phase Ib study of enzalutamide ± sorafenib in patients with advanced HCC. In part 1, a 3 + 3 dose de-escalation design with expansion established the recommended phase II dose (RP2D) of enzalutamide in patients in whom sorafenib treatment had failed. In part 2, a 3 + 3 dose escalation with expansion established the safety of enzalutamide with sorafenib in treatment-naive patients with HCC. Secondary objectives included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), pharmacokinetics (PK), and determination of AR expression by immunohistochemistry. A 7-day run-in with sorafenib alone in part 2 allowed assessment of the impact of enzalutamide on sorafenib pharmacokinetics. In part 1, 16 patients received enzalutamide 160 mg daily. No dose-limiting toxicity (DLT) occurred; 1 patient required dose reduction. Responses were not observed; median PFS and OS were 1.8 (95% confidence interval [CI]: 1.6-3.6) and 7 (95% CI: 3.6 to not reached [NR]) months, respectively. In part 2, patients received sorafenib 400 mg daily (4) or twice a day (8) both with enzalutamide at the recommended phase II dose-no DLTs were observed. ORR was 10% (95% CI: 0.3-44.5), and median PFS and OS were 2.9 (95% CI: 1.6 to NR) and 6.7 (95% CI: 4.6 to NR) months, respectively. Enzalutamide reduced sorafenib exposure by 60%. Tumor AR expression did not associate with outcome. Enzalutamide is ineffective in HCC; further development is not supported by this study.
Sections du résumé
LESSONS LEARNED
Androgen receptor as assessed by immunohistochemistry is expressed in a high proportion of patients with hepatocellular carcinoma (HCC). Enzalutamide at 160 mg orally daily is safe and tolerable in patients with advanced HCC but has no single-agent antitumor activity. Enzalutamide, a CYP3A4 inducer, at a standard dose of 160 mg reduces the exposure of sorafenib, a CYP3A4 substrate. Enzalutamide and sorafenib is safe and tolerable in patients with advanced HCC, but the addition of enzalutamide to sorafenib did not enhance the antitumor activity of sorafenib.
BACKGROUND
Androgen receptor (AR) interference is deleterious to hepatocellular carcinoma (HCC) in preclinical models.
METHODS
This is a multicenter, phase Ib study of enzalutamide ± sorafenib in patients with advanced HCC. In part 1, a 3 + 3 dose de-escalation design with expansion established the recommended phase II dose (RP2D) of enzalutamide in patients in whom sorafenib treatment had failed. In part 2, a 3 + 3 dose escalation with expansion established the safety of enzalutamide with sorafenib in treatment-naive patients with HCC. Secondary objectives included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), pharmacokinetics (PK), and determination of AR expression by immunohistochemistry. A 7-day run-in with sorafenib alone in part 2 allowed assessment of the impact of enzalutamide on sorafenib pharmacokinetics.
RESULTS
In part 1, 16 patients received enzalutamide 160 mg daily. No dose-limiting toxicity (DLT) occurred; 1 patient required dose reduction. Responses were not observed; median PFS and OS were 1.8 (95% confidence interval [CI]: 1.6-3.6) and 7 (95% CI: 3.6 to not reached [NR]) months, respectively. In part 2, patients received sorafenib 400 mg daily (4) or twice a day (8) both with enzalutamide at the recommended phase II dose-no DLTs were observed. ORR was 10% (95% CI: 0.3-44.5), and median PFS and OS were 2.9 (95% CI: 1.6 to NR) and 6.7 (95% CI: 4.6 to NR) months, respectively. Enzalutamide reduced sorafenib exposure by 60%. Tumor AR expression did not associate with outcome.
CONCLUSION
Enzalutamide is ineffective in HCC; further development is not supported by this study.
Identifiants
pubmed: 32548867
doi: 10.1634/theoncologist.2020-0521
pmc: PMC8186405
doi:
Substances chimiques
Antineoplastic Agents
0
Benzamides
0
Nitriles
0
Phenylurea Compounds
0
Phenylthiohydantoin
2010-15-3
Niacinamide
25X51I8RD4
enzalutamide
93T0T9GKNU
Sorafenib
9ZOQ3TZI87
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1825-e1836Subventions
Organisme : NCI NIH HHS
ID : K08 CA248964
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Informations de copyright
© AlphaMed Press; the data published online to support this summary are the property of the authors.
Références
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Lancet. 2010 Apr 24;375(9724):1437-46
pubmed: 20398925
Clin Cancer Res. 2004 Dec 15;10(24):8728-34
pubmed: 15623658
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Gastroenterology. 2008 Sep;135(3):947-55, 955.e1-5
pubmed: 18639551
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
J Clin Oncol. 2005 Feb 10;23(5):965-72
pubmed: 15613696
J Natl Cancer Inst. 2000 Dec 20;92(24):2023-8
pubmed: 11121465
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Hepatology. 2018 Jun;67(6):2271-2286
pubmed: 29220539
Hepatology. 2019 Feb;69(2):498-512
pubmed: 30070724
Nat Commun. 2018 Dec 6;9(1):5214
pubmed: 30523261
Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50
pubmed: 15508101
Oncotarget. 2017 Nov 25;8(65):109271-109288
pubmed: 29312607
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Cancer Res. 2020 Feb 1;80(3):561-575
pubmed: 31685543
Hepatology. 2004 Dec;40(6):1361-9
pubmed: 15565568
J Natl Cancer Inst. 2015 Jul 23;107(10):
pubmed: 26206949
J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6
pubmed: 23632345